Our multicenter analysis is the largest to date in this population and showed that the addition of rituximab to CODOX-M/IVAC chemotherapy confers no increase in toxicity and results in significantly improved OS and PFS in PLWH with Burkitt lymphoma who receive concomitant combination antiretroviral therapy.
ResultsSeventy-five patients with poor-prognosis disease, according to International Germ Cell Cancer Collaborative Group classification, received GAMEC as initial therapy. With a median follow-up of 63 months, the median progression-free survival (PFS) was >14 months. The 2-year PFS rate was 61.5% (95% confidence interval [CI] 49.1-71.6), and the 3year overall survival (OS) rate was 71.9%. Seventy-six patients received GAMEC as second-line therapy (following failure of bleomycin, etoposide and cisplatin or etoposide cisplatin). The median PFS was 7.5 months (95% CI 5.2-not evaluable), the 2-year PFS rate was 43.5% (95% CI 32.1-54.4) and the 3year OS rate was 53.7% (95% CI 41.6-64.3). In the third-line setting (n = 11), the 2-year PFS was 18.2% (95% CI 2.8-44.2). Overall, the treatment-related death rate declined from 10.5% in the first 15 years to 2.6% in the last 5 years. ConclusionGAMEC was an effective regimen in untreated poorprognosis disease and on relapse following conventional cisplatin and etoposide-based chemotherapy. Risk categorization based on LDH/age is more sensitive than that based on the updated IPFSG criteria. It is possible to identify patients who are particularly likely to benefit from this treatment, which has the important advantages of short duration and absence of bleomycin, particularly in patients with central nervous system and mediastinal disease. Lowdose induction treatment is associated with safer delivery of treatment without compromising survival.
Background. Treatment failure after allogeneic haematopoietic stem-cell transplantation (AHST) using reduced-intensity conditioning (RIC) results from too much alloreactivity and harmful acute Graft-versus-Host Disease (aGVHD). Studies have identified many reconstituting immune cell subsets associated with development of clinical alloreactivity but the functionally dominant parameters at different time-points remain unknown. We therefore used mass cytometry (MS) to simultaneously assess multiple alloreactive and immunoregulatory cell populations to identify dominant immune reconstitution signatures associated with subsequent development of aGvHD after AHST. Methods. Phenotypic markers identifying more than 30 immune cell subsets known to influence alloreactivity were combined in a single MS panel. Peripheral blood from 58 patients with haematological cancers was analysed after T-replete HLA-matched RIC-AHST using uniform conditioning. Normalization of individual test samples spiked with CD45-barcoded healthy control cells was used to reduce batch effects. Complementary high-dimensional analytic tools were used to generate cellular profiles across the whole cohort and identify differences between patients grouped by subsequent development of aGVHD. Results. Unsupervised clustering analysis identified 40 phenotypically distinct T, B and NK cell clusters post-transplant. Significant batch effects were effectively reduced with a novel R-based algorithm normalising data to control cells. Cluster diversity analysis early post-transplant demonstrated lower cluster diversity in patients who subsequently developed aGvHD consistent with perturbation of phenotypic clusters in these patients. Two specific clusters were significantly different in abundance at D+30 in patients who went on to develop aGvHD and those who remained aGVHD-free. A cluster with a CD56brightCD16negCD27+/- regulatory NK cell (NKreg) phenotype was reduced in patients going on to develop aGvHD using both Phenograph and FlowSOM algorithms (p=0.001). These findings were validated by forward analysis using the CITRUS algorithm, revealing a similar differentiating cell population. CD56bright NKreg reconstitution was independent of CMV reactivation and did not impede reconstitution of WT1 and PR1 tumor-associated antigen-specific T cells. The reduction in NKreg in patients who subsequently developed aGvHD was accompanied by a significant increase in alloreactive CCR5+CD45RA-CCR7- CD4 effector memory T cells (Tem). We next used correlation analysis of cluster abundance across the whole cohort to identify all clusters contributing to the immune 'regulome' (those inversely correlated with alloreactive CD4 EM and/or CD8 EM T cell clusters). Notably, at D+30 the regulome consisted of 4 phenotypically distinct CD56bright NKreg clusters and a CD4+CD8+ double positive (DP) cluster, but not FOXP3+ CD4 regulatory T cells (Treg), Figure 1A Both the identity of differentiating clusters between patients subsequently developing aGVHD and those who remained aGvHD-free, and the dominant constituents of the regulome changed over time. By D+60 a CD56bright NKreg cluster (with a distinct phenotype to the differentiating cluster identified at D+30) and a DP T cell cluster were significantly reduced in patients subsequently developing aGvHD. The D+60 regulome consisted of multiple distinct CD56bright clusters, a DP T cell cluster and CD4 Treg, Figure 1B. Importantly by D+90 the immune regulome consisted of a reduced number of CD56bright NKreg clusters and increasing dominance of CD4Treg, Figure 1C. Conclusion. We show proof-of-concept that a novel acquisition and analysis pipeline can be applied to MS data to identify multiple immunoregulatory cells after AHST that contribute to the control of reconstituting alloreactive T cells. This approach identified a loss of NK cell-mediated control of alloreactive CD4 Tem cells as the dominant immune process preceding the development of aGvHD early post-transplant. Importantly, we show that specific immunoregulatory subsets are dominant at different time-points, with increasing influence of DP T cells and CD4 Treg at later time points. Our data provide mechanistic insight into the dynamic pattern of control of alloreactivity over time and show that strategies to expand or potentiate immunoregulatory cells to prevent aGvHD should be time-dependent. Disclosures Gribben: Acerta/Astra Zeneca: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.